Answers are grounded in this paper and cite their sources.
Background Insulin-like growth factor (IGF) signaling drives progression of glioblastoma (GBM), the most aggressive brain cancer. While sphingolipid metabolism is implicated in gliomagenesis, the mechanism by which it regulates GBM growth and therapy response is poorly understood. Methods Through bioinformatic analyses of human gliomas, we identified sphingolipid metabolism genes with potential functional significance in glioma. Using patient-derived cells, a Drosophila glioma model, and xenograft mouse models, we investigated the functional role of Dihydroceramide desaturase 1 (DEGS1). Lipidomics profiling and RNA sequencing were performed in patient-derived cells to reveal the mechanism by which DEGS1 regulates glioma growth. Additionally, we tested the effect of a DEGS1 inhibitor on GBM cell growth and their resistance to IGF1R-targeted therapy. Results Our data demonstrate that the expression of sphingolipid metabolism gene DEGS1 is associated with aggressive glioma biomarkers and worse patient survival. DEGS1 is required for glioma growth in patient-derived cells, a Drosophila glioma model, and xenograft mouse models. Lipidomics profiling reveals that DEGS1 deficiency results in reduced ceramides and complex sphingolipids and accumulation of their precursors. Disrupted sphingolipid homeostasis impairs lipid raft biogenesis and lipid raft-associated IGF signaling. Targeting DEGS1 decreases GBM cell growth and their resistance to IGF1R inhibition. Conclusions These findings establish that targeting DEGS1-regulated sphingolipid metabolism is a viable avenue to inhibit IGF signaling-driven GBM growth.
No takes yet. Share an insight, caveat, or question.
Liu et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: